REDWOOD CITY, CA (January 3rd, 2012) – myoscience, Inc. of Redwood City, California is pleased to announce the appointment of Robert E. Grant as Chairman of the Board of Directors effective January 1st, 2012. Mr. Grant was formerly Chief Executive Officer and President of Bausch & Lomb Surgical and President of Allergan Medical, a division of Allergan (NYSE: AGN). Mr. Grant has been a board member for myoscience since November 2010 and this latest announcement is a reflection of the company’s continuing development as a commercial company in the global aesthetics market.
“We are pleased that Robert has agreed to take the Chairman’s role at this important stage of our success. I have the utmost respect for his strategic talent and his deep understanding of the medical device and pharmaceutical markets,” said Clint Carnell, President and Chief Executive Officer of myoscience. “I would also like to thank Rich Ferrari of DeNovo Ventures. Rich led the Board since its inception and we look forward to his continued contributions as a myoscience board member.”
“myoscience’s next generation, toxin-free approach to treating nerves for aesthetic and therapeutic applications represents a major advance in neuromodulation. Clint is an adept leader and manager. He has assembled a talented management team and positioned the company for international commercial launch following recent regulatory approvals in both the EU and Canada.” said Mr. Grant.
About myoscience
Myoscience is a privately held medical device company dedicated to developing innovative treatments in whichever fields it chooses to enter. The myoscience technology is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions and focal cryo-treatment of tissue. The myoscience technology has also been cleared in the US for use in pain management and general surgical use. www.myoscience.com
